ThermiGen, LLC

The ThermiAesthetics flagship product is the ThermiRF Temperature Controlled Radio Frequency Generator System. The ThermiRF device is designed for the MICRO-invasive ablation and coagulation of nervous and sub-dermal soft tissue, as well as the non-invasive treatment of skin laxity and wrinkles.  ThermiRF is a platform technology, which may be configured for multiple applications in the aesthetic medical marketplace.

ThermiRF features a unique temperature-control feature, and uses proprietary hand pieces, which are designed for specific medical applications.  These include a variety of disposable RF electrodes and cannulas, and reusable non-invasive hand pieces.
ThermiRF is an advanced technology using finely controlled thermal energy. It is a multi-use platform, which promotes increased patient safety, comfort and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market with minimally invasive and non-invasive procedures.  Minimally invasive procedures are defined as those, which require minor incisions under the skin, and typically offer reduced downtime and lower risk of complications than traditional surgery.

The management team at Thermi Aesthetics is committed to building a platform of growth and a value opportunity for its members, Clinical Advisory Council, employees, customers and other partners. ThermiAesthetics marks the reuniting of Paul Herchman and Kevin O’Brien, who together in 1989 founded, developed and operated Medical Alliance, Inc., a nationwide pioneer in mobile surgical and aesthetic technology services. Under Herchman and O’Brien’s leadership, Medical Alliance, Inc. was designated as the 7th fastest growing private company by the Dallas 100 awards sponsored by the SMU Cox School of Business, and in 1994 was named by Inc. magazine as the 317th fastest growing private company in the United States.  In 1996, MAI completed its IPO in an offering underwritten by Bear Stearns, was listed on NASDAQ as MAI, and at the end of 2000, the Company was sold to ICN Pharmaceuticals, Inc.